05/20/2026
La ménopause accélère le vieillissement cérébral. Plus elle survient tôt, plus le cerveau vieillit.
Traduction: "Pendant des décennies, on a dit aux femmes qui se plaignaient de troubles cognitifs, de changements cognitifs ou de problèmes de mémoire liés à la ménopause que cela était dû au stress, au sommeil ou « simplement au vieillissement ». Une nouvelle étude protéomique du plasma menée par UK Biobank suggère que cette explication était incomplète.
Alexander et al. (2026) ont mesuré les protéines circulantes chez 15 012 femmes ménopausées et ont examiné leur corrélation avec l'âge à la ménopause. La tendance était claire. Une ménopause précoce était associée à une régulation à la hausse des voies pro-inflammatoires et de dégradation de la matrice extracellulaire, ainsi qu'à un vieillissement accéléré selon les horloges protéomiques du vieillissement des organes et des cellules. (...) Plus la ménopause survenait tôt, plus ces signaux protéomiques semblaient accélérés.
La principale protéine corrélée était le GDF15, décrit par les auteurs comme un marqueur canonique du vieillissement. La signature protéique complète associée à la ménopause a également montré des associations concordantes avec quatre résultats cérébraux en aval dans la même cohorte : le risque d'incidence de démence, l'atrophie cérébrale, la charge de la maladie des petits vaisseaux cérébraux et l'intégrité microstructurale de la substance blanche.
(...)
Quelques précisions importantes. Il s'agit d'un prépublication de Research Square, qui n'a pas encore fait l'objet d'une évaluation par les pairs. Les données sont observationnelles.
- William Wallace, PhD.
For decades, women reporting brain fog, cognitive changes, or memory issues around menopause were told it was stress, sleep, or "just aging." A new plasma proteomics study from UK Biobank suggests that explanation was incomplete.
Alexander et al. (2026) measured circulating proteins in 15,012 postmenopausal women and looked at how they correlated with age at menopause. The pattern was clear. Earlier menopause was associated with upregulation of pro-inflammatory and extracellular matrix degradation pathways, plus accelerated aging across proteomic clocks of organ and cellular aging. Two of those clocks were a brain aging clock and an oligodendrocyte aging clock. The earlier menopause occurred, the more accelerated those proteomic signals looked.
The top single protein correlate was GDF15, described by the authors as a canonical aging marker. The full menopause-associated protein signature also showed concordant associations with four downstream brain outcomes in the same cohort: incident dementia risk, brain atrophy, cerebral small vessel disease burden, and white matter microstructural integrity.
The signal replicated in an independent cohort of 1,210 postmenopausal women from the Women's Health Initiative Long Life Study. Replication in a second cohort is one of the most important quality markers for an observational proteomics result, and this one cleared it.
A few important calibrations. This is a Research Square preprint, not yet peer-reviewed. The data is observational, not experimental. It shows correlation between menopause timing and proteomic brain aging signatures, not causation. The brain aging clocks themselves are research tools, not clinical diagnostics.
What's actionable now:
If menopause occurred before 45, especially before 40, the cardiovascular and cognitive risk profile is different. Current guidelines from the Menopause Society, the International Menopause Society, and ESHRE generally support hormone therapy until at least average menopause age, around 51, for women with early or premature menopause, barring contraindications. That conversation belongs with a clinician familiar with menopause medicine, not with anyone telling you it's "just stress."
The brain aging factors with the strongest human RCT evidence are not menopause-specific. Aerobic exercise has the most consistent data for slowing brain atrophy and preserving white matter integrity. Sleep quality affects glymphatic clearance. Cardiovascular risk control, including blood pressure, glucose, and lipid management, directly reduces the small vessel disease burden flagged as one of the brain outcomes in this paper. These work regardless of menopause timing, but they matter more if menopause was earlier.
Track menopause timing. It's a permanent line in your health record that informs how aggressively to pursue the items above. Vague "perimenopause started somewhere in my forties" is not the same data point as "my last menstrual cycle was at 42."
Don't accept dismissal. Cognitive complaints during the menopause transition have measurable biological correlates in the blood. The plasma proteomics is starting to close a research gap that should never have existed.
Alexander et al., Research Square preprint, 2026
